RÉSUMÉ
A 62-year-old female patient presents with myalgia, dysphagia and daytime fatigue. Clinical examination is normal. Laboratory results show a hyperthyroidism and an increased erythrocyte sedimentation rate. Clinical presentation, an ultrasound and further examinations suggest a thyroiditis de Quervain. A treatment with NSAR is started. After eight weeks the thyroid hormones return to normal and the patient is asymptomatic.
Sujet(s)
Troubles de la déglutition/étiologie , Fatigue/étiologie , Maladies musculaires/étiologie , Douleur/étiologie , Thyroïdite subaigüe/diagnostic , Sédimentation du sang , Diagnostic différentiel , Femelle , Humains , Hyperthyroïdie/diagnostic , Adulte d'âge moyenRÉSUMÉ
A 33 year old man is evaluated for a pruriginous plantar eruption on the right foot. Three weeks ago he walked across a river barefoot in the south of Vietnam. In the clinical examination of the foot a red, serpiginuous dermatitis was seen. Patient history and clinical picture were typical for a larva migrans. After starting a treatment with albendazol the patient felt well and the lesions disappeared.
Sujet(s)
Pays en voie de développement , Dermatoses du pied/étiologie , Larva migrans/diagnostic , Prurit/étiologie , Voyage , Adulte , Albendazole/usage thérapeutique , Anthelminthiques/usage thérapeutique , Diagnostic différentiel , Humains , Larva migrans/traitement médicamenteux , MâleRÉSUMÉ
Schnitzler's syndrome is a rare disease characterized by the association of chronic urticaria, intermittent fever, bone pain, arthritis, and monoclonal IgM gammopathy. It was first described by the French dermatologist Liliane Schnitzler in 1974. Because of the variety of clinical signs, the syndrome is of concern to doctors of different specialties and is of special interest to internists, rheumatologists, hematologists and dermatologists. Up to now, treatment was often difficult and disappointing. Interleukin-1 receptor antagonists offer a new therapeutic option.
Sujet(s)
Syndrome de Schnitzler/diagnostic , Urticaire/étiologie , Vascularite/étiologie , Biopsie , Moelle osseuse/anatomopathologie , Diagnostic différentiel , Fièvre d'origine inconnue/étiologie , Granulocytes/anatomopathologie , Humains , Chaines légères des immunoglobulines/sang , Immunoglobuline M/sang , Chaines lambda des immunoglobulines/sang , Mâle , Adulte d'âge moyen , Granulocytes neutrophiles/anatomopathologie , Paraprotéinémies/diagnostic , Paraprotéinémies/anatomopathologie , Syndrome de Schnitzler/anatomopathologie , Peau/anatomopathologie , Urticaire/anatomopathologie , Vascularite/anatomopathologieRÉSUMÉ
OBJECTIVE: To determine whether injections of botulinum toxin could be of therapeutic value in the treatment of tension-type headache. BACKGROUND: Botulinum toxin A is very effective at reducing muscle tenderness and pain in many diseases. Increased muscle tension may contribute to tension-type headache. METHODS: We performed a double-blind, placebo-controlled study with 21 patients fulfilling the International Headache Society criteria for tension-type headache. Participants were randomly assigned to treatment (pericranial injection of 10 x 20 mouse units botulinum toxin A) or placebo (injection of isotonic saline in the same manner). RESULTS: After 4, 8, and 12 weeks, no significant differences between placebo and treatment could be observed (with respect to visual analog scale, frequency and duration of headache attacks, consumption of analgesics, pressure pain threshold, total tenderness score, and quality-of-life parameters). CONCLUSIONS: The findings of our study strongly support the hypothesis that peripheral mechanisms, such as increased muscle tenderness, only play a minor role in the pathogenesis of tension-type headache.